HC Wainwright降低萨雷普塔治疗药品的价格目标, HC Wainwright lowers Sarepta Therapeutics' price target, contributing to an overall "Hold" rating.

HC Wainwright重申了萨雷普塔治疗学(NASDAQ:SRPT)的“销售”评级,将价格目标降至40美元。 HC Wainwright has reaffirmed a "sell" rating for Sarepta Therapeutics (NASDAQ:SRPT), lowering the price target to $40. JP摩根和德意志银行等其他公司也削减了价格目标。 Other firms like JPMorgan and Deutsche Bank have also cut their price targets. Sarepta治疗法的重点是针对RNA的治疗和稀有疾病的基因疗法。 Sarepta Therapeutics focuses on RNA-targeted therapeutics and gene therapies for rare diseases. 该公司目前的平均“等待”评级为60.88美元,协商一致价格目标是60.88美元。 The company currently has an average "Hold" rating with a consensus price target of $60.88.